Published January 1, 2025 | Version v1
Journal article Open

Dual-drug-loaded magnetic lipid based nanobubbles are effective in non-small cell lung cancer treatment: in vitro and in vivo studies

  • 1. Ege Univ, Fac Sci, Dept Biochem, Izmir, Turkiye
  • 2. Trakya Univ, Fac Pharm, Pharmaceut Biotechnol Dept, Edirne, Turkiye
  • 3. Cukurova Univ, Fac Med, Med Biochem Dept, Adana, Turkiye
  • 4. Rhenish Friedrich Wilhelm Univ Bonn, Pharm Inst, Pharmaceut Technol, Bonn, Germany
  • 5. Ege Univ, Lab Anim Applicat & Res Ctr, Izmir, Turkiye
  • 6. Uludag Univ, Fac Vet Med, Dept Physiol, Bursa, Turkiye
  • 7. Ege Univ, Fac Med, Dept Histol & Embryol, Izmir, Turkiye
  • 8. Ege Univ, Fac Sci, Dept Biol, Izmir, Turkiye
  • 9. Ege Univ, Fac Engn, Dept Bioengn, Izmir, Turkiye
  • 10. Ege Univ, Fac Sci, Dept Stat, Izmir, Turkiye
  • 11. Ataturk Univ, Fac Sci, Mol Biol & Genet, Erzurum, Turkiye

Description

The high rate of lung cancer and related deaths necessitated new treatment strategies. This study aimed at in vitro, in vivo, and ex vivo evaluation of magnetic field sensitive, ultrasound-mediated, and pemetrexed and pazopanib containing nanobubble (NB) destruction to provide dual drug therapy against non-small cell lung cancer. For this purpose, cytotoxicity analysis (CRL-5807, CRL-5826, A549-Luc-C8), biocompatibility experiments including hemocompatibility, uptake by macrophages, and binding to serum proteins, acute and long-term toxicity analyses, in vivo therapeutic efficacy experiments, pharmacokinetic analyses, histochemistry, and immunohistochemistry experiments were performed on NBs. The IC50 value of NB-400 against A549-Luc-C8 was found to be 31.4 +/- 1.6 mu g/mL and 34.9 +/- 1.2 mu g/mL with and without ultrasound application for 72 h, respectively. 30.8% of NB-400 was phagocytosed by macrophage cells and was non-hemolytic. It was determined that NB-800 (prepared for inhaler administration) and NB-400 did not cause acute or long-term toxic effects and reduced tumor size and/or disappeared after treatment, but carrier-free dual drugs did not give a therapeutic response also based on immunohistochemical analyses. It can be said that the emerging intravenous and inhaled delivery systems can be potential therapeutics that can be used in the treatment of non-small cell lung cancer with superior properties such as magnetic targeting and ultrasound sensitivity.

Files

bib-fcf5c0e3-f71b-467e-b3e3-00a27c11d285.txt

Files (390 Bytes)

Name Size Download all
md5:618e3633e2634abe8eb6ec5de6510664
390 Bytes Preview Download